Indeed Snapshot

Track Alexion Pharmaceuticals reviews on Indeed to uncover insights on employee sentiment
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated GICS Sector GICS Industry
nasdaq:alxn https://www.indeed.com/cmp/alexion-pharmaceuticals,inc. Sep 18th, 2021 12:00AM Open Alexion Pharmaceuticals,Inc. Pharmaceuticals Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. (Source: 10-K) RRv1_1B_5B 3.60 79.0 73.0 80.0 76.0 67.0 72.0 67.0 71.0 65.0 70.0 75.0 75.0 30.0 166.00 20.00 About two weeks 22.00 MEDIUM 22.00 FAVORABLE Sep 18th, 2021 06:34AM Sep 18th, 2021 06:34AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/synageva-biopharma Sep 18th, 2021 12:00AM Open Synageva BioPharma Pharmaceutical & Biotechnology Synageva BioPharma is a publicly traded biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva was formed to concentrate on novel orphan treatments for rare diseases. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is in clinical development and has been granted orphan designation by the FDA. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality. Synageva has additional orphan products in development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven record of discovery, development and commercial experience within rare diseases. Our work is based on creating value for patients and their healthcare providers, our shareholders and our employees. Our success brings new treatments to patients and providers. We are building a sustainable business and value for our shareholders because good medicine is good business. Our culture attracts and retains principle-minded individuals of integrity, drive, energy and passion. 4.00 5.00 Sep 18th, 2021 06:34AM Sep 18th, 2021 06:34AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/achillion-pharmaceuticals Sep 18th, 2021 12:00AM Open Achillion Pharmaceuticals 4.70 3.00 3.00 5.00 4.70 4.00 5.00 4.70 Sep 18th, 2021 06:34AM Sep 18th, 2021 06:34AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/alexion-pharmaceuticals,inc. Sep 16th, 2021 12:00AM Open Alexion Pharmaceuticals,Inc. Pharmaceutical & Biotechnology Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. (Source: 10-K) RRv1_1B_5B 3.60 79.0 73.0 80.0 76.0 67.0 72.0 67.0 71.0 65.0 70.0 75.0 75.0 30.0 166.00 166.00 3.20 4.30 2.90 3.20 3.30 20.00 About two weeks 22.00 MEDIUM 22.00 FAVORABLE Sep 16th, 2021 05:40AM Sep 16th, 2021 05:40AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/synageva-biopharma Sep 16th, 2021 12:00AM Open Synageva BioPharma Pharmaceutical & Biotechnology Synageva BioPharma is a publicly traded biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva was formed to concentrate on novel orphan treatments for rare diseases. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is in clinical development and has been granted orphan designation by the FDA. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality. Synageva has additional orphan products in development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven record of discovery, development and commercial experience within rare diseases. Our work is based on creating value for patients and their healthcare providers, our shareholders and our employees. Our success brings new treatments to patients and providers. We are building a sustainable business and value for our shareholders because good medicine is good business. Our culture attracts and retains principle-minded individuals of integrity, drive, energy and passion. 4.00 5.00 Sep 16th, 2021 05:40AM Sep 16th, 2021 05:40AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/achillion-pharmaceuticals Sep 16th, 2021 12:00AM Open Achillion Pharmaceuticals 4.70 3.00 3.00 5.00 4.70 4.00 5.00 4.70 Sep 16th, 2021 05:40AM Sep 16th, 2021 05:40AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/alexion-pharmaceuticals,inc. Sep 15th, 2021 12:00AM Open Alexion Pharmaceuticals,Inc. Pharmaceutical & Biotechnology Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. (Source: 10-K) RRv1_1B_5B 3.60 79.0 73.0 80.0 76.0 67.0 72.0 67.0 71.0 65.0 70.0 75.0 75.0 30.0 166.00 166.00 3.20 4.30 2.90 3.20 3.30 20.00 About two weeks 22.00 MEDIUM 22.00 FAVORABLE Sep 15th, 2021 05:45AM Sep 15th, 2021 05:45AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/synageva-biopharma Sep 15th, 2021 12:00AM Open Synageva BioPharma Pharmaceutical & Biotechnology Synageva BioPharma is a publicly traded biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva was formed to concentrate on novel orphan treatments for rare diseases. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is in clinical development and has been granted orphan designation by the FDA. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality. Synageva has additional orphan products in development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven record of discovery, development and commercial experience within rare diseases. Our work is based on creating value for patients and their healthcare providers, our shareholders and our employees. Our success brings new treatments to patients and providers. We are building a sustainable business and value for our shareholders because good medicine is good business. Our culture attracts and retains principle-minded individuals of integrity, drive, energy and passion. 4.00 5.00 Sep 15th, 2021 05:45AM Sep 15th, 2021 05:45AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/achillion-pharmaceuticals Sep 15th, 2021 12:00AM Open Achillion Pharmaceuticals 4.70 3.00 3.00 5.00 4.70 4.00 5.00 4.70 Sep 15th, 2021 05:45AM Sep 15th, 2021 05:45AM Health Care Pharmaceuticals & Biotechnology
nasdaq:alxn https://www.indeed.com/cmp/alexion-pharmaceuticals,inc. Sep 14th, 2021 12:00AM Open Alexion Pharmaceuticals,Inc. Pharmaceutical & Biotechnology Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. (Source: 10-K) RRv1_1B_5B 3.60 79.0 75.0 82.0 78.0 68.0 74.0 68.0 73.0 67.0 72.0 77.0 77.0 29.0 166.00 166.00 3.20 4.30 2.90 3.20 3.30 20.00 About two weeks 22.00 MEDIUM 22.00 FAVORABLE Sep 14th, 2021 06:13AM Sep 14th, 2021 06:13AM Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.